IGFBP2 and cancer: The most effective biomarker panel was IGFBP2 : LCAT : CA125; this panel outperformed CA125 in terms of sensitivity at nearly all time points measured for the Type I and Type II cancers, with at least a doubling in the sensitivity of the panel at 0–2 years’ pre-diagnosis for Type I OC and a greater than tripling in sensitivity for Type II at 1–2 and >4 years tDx.